Therapy Areas: Respiratory
3SBio signs biosimilar collaboration agreement with Samsung Bioepis
7 January 2019 -

Chinese biopharmaceutical company 3SBio Inc (01530.HK) revealed on Sunday the launch of a collaboration agreement with Samsung Bioepis Co Ltd for the clinical development and commercialisation of multiple biosimilar candidates.

This partnership will cover the clinical development and commercialisation of multiple biosimilar candidates developed by Samsung Bioepis, including SB8 Bevacizumab biosimilar candidate (SB8) in China (excluding Hong Kong, Macau and Taiwan).

The indications of Bevacizumab biosimilar candidate in China will focus on metastatic colon cancer (mCRC) and Non-Small Cell Lung Cancer (NSCLC). Bevacizumab is a recombinant humanized monoclonal antibody and in 2004 it became the first clinically used angiogenesis inhibitor.

Under the terms of the agreement, Samsung Bioepis will be responsible for manufacturing and supply of the products and collaborate with 3SBio across clinical development, regulatory registration and commercialization in China.

In conjunction with the partnership, Samsung Bioepis will receive an upfront payment and product supply income from 3SBio and will be eligible for additional payments associated with pre-specified clinical and regulatory milestones. Further financial terms were not disclosed.

Login
Username:

Password:


Related Headlines